Latest On REGENXBIO Inc (RGNX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-23 17:08 EST | News | Regenxbio's gene therapy for Hunter syndrome gets FDA regenerative medicine status | N/A |  |
| 2023-05-12 13:54 EST | News | Regenxbio: Buy, High-Potential Stock Stagnant Due To No Near-Term Catalysts | N/A | |
| 2023-05-04 03:36 EST | News | Regenxbio GAAP EPS of -$1.53 misses by $0.14, revenue of $19.14M misses by $12.15M | N/A | |
| 2023-05-04 03:36 EST | News | REGENXBIO Inc. (RGNX) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-03 02:13 EST | News | Regenxbio Q1 2023 Earnings Preview | N/A | |
About REGENXBIO Inc (RGNX):
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid read more...lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
General
- Name REGENXBIO Inc
- Symbol RGNX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 306
- Fiscal Year EndDecember
- IPO Date2015-09-17
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.regenxbio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 9.47
- Price/Book (Most Recent Quarter) 4.42
- Enterprise Value Revenue 8.19
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$5.06
- Next Year EPS Estimate -$5.20
- Next Quarter EPS Estimate -$1.32
- Profit Margin -72%
- Operating Margin -77%
- Return on Assets -12%
- Return on Equity -27%
- Revenue 154.57 million
- Earnings Per Share -$1.36
- Revenue Per Share $4.15
- Gross Profit -47441000
- Quarterly Earnings Growth 82.2%
Highlights
- Market Capitalization 1.78 billion
- EBITDA -87438000
- PE Ratio -2.51
- PEG Ratio 0.26
- Analyst Target Price $63.22
- Book Value Per Share $10.08
Share Statistics
- Shares Outstanding 42.5 million
- Shares Float 36.95 million
- % Held by Insiders 1454%
- % Held by Institutions 89.9%
- Shares Short 2.94 million
- Shares Short Prior Month 2.66 million
- Short Ratio 7.52
- Short % of Float 10%
- Short % of Shares Outstanding 7%
Technicals
- Beta 1.2
- 52 Week High $50.26
- 52 Week Low $25.93
- 50 Day Moving Average 42.78
- 200 Day Moving Average 37.27
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
REGENXBIO Inc (RGNX) Dividend Calendar:
REGENXBIO Inc (RGNX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
REGENXBIO Inc (RGNX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
REGENXBIO Inc (RGNX) Chart:
REGENXBIO Inc (RGNX) News:
Below you will find a list of latest news for REGENXBIO Inc (RGNX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
REGENXBIO Inc (RGNX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest RGNX Trades:
REGENXBIO Inc (RGNX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 8-K (Current report) | |
| 2020-11-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-27 | 8-K (Current report) | |
| 2020-09-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-18 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 8-K (Current report) | |
| 2020-07-02 | 8-K (Current report) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 8-K (Current report) | |
| 2020-05-12 | 4 (Statement of changes in beneficial ownership of securities) | |
REGENXBIO Inc (RGNX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of REGENXBIO Inc (RGNX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1454%
Institutional Ownership: 8990%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-07-15 | Vittal Vasista | Chief Financial Officer | Sell | 14,950.00 | 40.10 | 599,495.00 | 195,024.00 | |
| 2020-07-15 | Vittal Vasista | Chief Financial Officer | Buy | 3,259.00 | 13.09 | 42,660.31 | 209,974.00 | |
| 2020-05-11 | Vittal Vasista | Chief Financial Officer | Sell | 500.00 | 40.00 | 20,000.00 | 206,715.00 | |
| 2020-05-11 | Vittal Vasista | Chief Financial Officer | Buy | 500.00 | 13.09 | 6,545.00 | 207,215.00 | |
| 2020-05-08 | Vittal Vasista | Chief Financial Officer | Sell | 7,000.00 | 40.18 | 281,260.00 | 206,715.00 | |
| 2020-05-08 | Vittal Vasista | Chief Financial Officer | Buy | 2,500.00 | 13.09 | 32,725.00 | 213,715.00 | |
| 2020-04-24 | Vittal Vasista | Chief Financial Officer | Sell | 12,000.00 | 40.11 | 481,320.00 | 211,215.00 | |
| 2020-04-24 | Vittal Vasista | Chief Financial Officer | Buy | 3,000.00 | 13.09 | 39,270.00 | 223,215.00 | |
| 2020-04-23 | Vittal Vasista | Chief Financial Officer | Sell | 3,000.00 | 40.00 | 120,000.00 | 220,215.00 | |
| 2020-04-23 | Vittal Vasista | Chief Financial Officer | Buy | 3,000.00 | 13.09 | 39,270.00 | 223,215.00 | |
| 2020-03-31 | Vittal Vasista | Chief Financial Officer | Buy | 10,000.00 | 0.85 | 8,500.00 | 220,215.00 | |
| 2020-02-11 | Curran Simpson | SVP, Product Development & CTO | Buy | 6,633.00 | 22.00 | 145,926.00 | 16,512.00 | |
| 2020-02-11 | Curran Simpson | SVP, Product Development & CTO | Sell | 3,692.00 | 51.37 | 189,658.04 | 3,948.00 | |
| 2020-02-11 | Curran Simpson | SVP, Product Development & CTO | Sell | 8,872.00 | 50.13 | 444,753.36 | 7,640.00 | |
| 2020-02-10 | DONALD J JR HAYDEN | Director | Sell | 24,800.00 | 50.11 | 1,242,728.00 | 0.00 | |
| 2020-02-10 | Vittal Vasista | Chief Financial Officer | Sell | 14,129.00 | 50.12 | 708,145.48 | 210,215.00 | |
| 2020-02-10 | Vittal Vasista | Chief Financial Officer | Sell | 677.00 | 49.05 | 33,206.85 | 224,344.00 | |
| 2020-02-10 | Vittal Vasista | Chief Financial Officer | Buy | 3,000.00 | 13.09 | 39,270.00 | 225,021.00 | |
| 2020-02-10 | DONALD J JR HAYDEN | Director | Buy | 24,800.00 | 0.85 | 21,080.00 | 24,800.00 | |
| 2020-02-10 | Curran Simpson | SVP, Product Development & CTO | Buy | 4,253.00 | 19.50 | 82,933.50 | 26,901.00 | |